Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
AMPK alpha 2 Lentiviral Activation Particles (h): sc-400277-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- AMPK alpha 2 Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- AMPK alpha 2 Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by AMPK alpha 2 Lentiviral Activation Plasmid (h) and AMPK alpha 2 Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the PRKAA2 promoter. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AMPK alpha 2 Lentiviral Activation Particles (h) | sc-400277-LAC | 200 µl | $455.00 |
PRKAA2 encodes the catalytic α2 subunit of AMP-activated protein kinase (AMPK), a central energy sensor that coordinates cellular adaptation to nutrient and energetic stress. AMPKα2 integrates AMP/ADP-to-ATP ratio signals to regulate metabolic pathways including fatty acid oxidation, glucose uptake, mitochondrial biogenesis, and inhibition of anabolic programs via mTORC1 and related effectors. In human cells, AMPKα2 activity influences autophagy, redox homeostasis, and cell-cycle control, linking PRKAA2 to research on metabolic syndrome, type 2 diabetes, cardiovascular remodeling, and cancer-associated metabolic reprogramming. Its isoform-selective roles also support studies of tissue-specific energy balance, mitochondrial dynamics, and stress-response signaling.
AMPK alpha 2 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient PRKAA2 upregulation across a broader range of human cell types.
AMPK alpha 2 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the PRKAA2 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous AMPK alpha 2 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native PRKAA2 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.